CLBT
Cellebrite DI
NASDAQ: CLBT · TECHNOLOGY · SOFTWARE - INFRASTRUCTURE
$12.84
+0.00% today
Updated 2026-06-12
Market cap
$3.20B
P/E ratio
45.86
P/S ratio
6.45x
EPS (TTM)
$0.28
Dividend yield
—
52W range
$11 – $20
Volume
2.2M
Cellebrite DI (CLBT) Financial Forecast & Price Target 2030
Research-backed projections from analyst consensus, management guidance, and sector analysis.
Research-backed CLBT price target 2030 projection accounting for share dilution, balance sheet debt, and time value of money.
Current price
$12.84
Today
Analyst consensus
$21.75
+69.39% · 12M
2030 Base
$16.82
+31.00% future
NPV today
$10.48
@ 11% WACC
5 analysts:
4 Buy1 Hold0 Sell
Management guidance
CEO Thomas Hogan expects a significant rebound in federal growth in 2026 after a slowdown in 2025. Management guided Q2 2026 revenue of $130M-$133M (midpoint $131.5M), implying annualized run-rate of ~$526M-$532M for 2026. Company projects accelerated ARR expansion in Q2 2026 and full-year 2026 adjusted EBITDA of $149M-$155M, signaling confidence in sustained double-digit growth trajectory through 2027.
Sources: Management guidance, analyst consensus, sector analysishigh confidence
CLBT · Cellebrite DI · Revenue & price projection · 2023–2030E
Actual / 2030 target Projected revenue Base case price Bull to bear range
Bear case (2030)
$12.20
NPV today: $7.60
Base case (2030)
$16.82
NPV today: $10.48
Bull case (2030)
$35.26
NPV today: $21.98
WallStSmart.com
CLBT financial forecast · Research-backed projections
| Metric | 2025 | 2026 (E) | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) ★ |
|---|---|---|---|---|---|---|
| Revenue | $0.5B | $0.6B | $0.7B | $0.9B | $1.1B | $1.2B |
| Revenue growth | 18.6% | 25.1% | 25.2% | 21.5% | 16.5% | 12.8% |
| Net margin | — | 26.2% | 28.5% | 30.4% | 31.1% | 31.2% |
| EPS | $0.44 | $0.62 | $0.84 | $1.08 | $1.28 | $1.44 |
| Diluted shares | — | 251M | 253M | 255M | 256M | 258M |
| Net debt | — | $-98.81M | $-227.05M | $-382.84M | $-564.45M | $-769.30M |
| P/S multiple | — | 3.0x | 3.0x | 3.0x | 3.0x | 3.0x |
| Implied price (base) | — | $7.49 | $9.72 | $12.15 | $14.54 | $16.82 |
★ 2030E is the model's terminal target year. Implied price = (Revenue × P/S − Net debt) ÷ Diluted shares.
Scenario detail · Three drivers, three outcomes
| 2030E driver | Bear | Base | Bull |
|---|---|---|---|
| Revenue | $1.2B | $1.2B | $1.2B |
| P/S multiple | 2.0x | 3.0x | 7.0x |
| Diluted shares | 258M | 258M | 258M |
| Net debt | $-769.30M | $-769.30M | $-769.30M |
| Implied P/E † | 9x | 12x | 25x |
| 2030 Price | $12.20 | $16.82 | $35.26 |
| NPV @ 11% | $7.60 | $10.48 | $21.98 |
† Implied P/E: Multiples remain elevated across all three scenarios because CLBT is valued primarily on revenue scale during its growth phase, not near-term earnings power. Lower P/E in the bear case reflects multiple compression, but the absolute level stays high since 2030E still represents a hypergrowth-to-mature transition year.
EV to per-share bridge · How we get to $16.82 base case
CLBT catalysts and risks
Growth catalysts
+ FedRAMP High Authorization unlocking U.S. federal cloud workloads (estimated $2B+ TAM in government digital forensics)
+ Genesis agentic AI product launch (general availability mid-June 2026) expanding addressable market by estimated 2-3x
+ Federal spending rebound in 2026 after 2025 budget uncertainty, with CEO explicitly forecasting material federal growth acceleration
+ Drone forensics integration (SCG Canada acquisition) opening new $500M+ TAM vertical
+ ARR growth acceleration (21% YoY in Q1 2026) signaling subscription business maturation and predictable recurring revenue streams
Key risks
- U.S. federal government spending delays or policy changes affecting procurement timelines (public sector concentration risk)
- High P/E multiple (44-47x) leaves little margin for execution missteps; Q1 margin compression despite revenue growth
- Customer concentration in law enforcement/government (>60% of revenue) creates cyclical spending risk tied to budget cycles
- AI product monetization uncertainty: Genesis at early-stage; unclear if new AI capabilities command premium pricing or cannibalize existing products
- Insider selling activity (CRO sold 12,658 shares in May 2026) may signal concerns about near-term valuation
Methodology · Cellebrite DI 2030 stock forecast model
Cellebrite DI 2030 price target is calculated using WallStSmart's research model. Revenue projections are derived from analyst consensus across 5 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts. The model is built on five core components:
| 1. Share dilution | Projected from per-ticker schedule of SBC + equity raise activity, compounding year by year (3% cumulative for CLBT by 2030) |
| 2. Net debt | EV minus net debt yields equity value; debt projected from capex cycle trajectory ($-769.30M by 2030) |
| 3. Time value | NPV calculated using 11% WACC (CAPM: beta 1.146) |
| 4. Multiple framework | P/S compresses with scale: bear 2.0x / base 3.0x / bull 7.0x |
| 5. Scenario design | Bull/Base/Bear vary revenue, margin, shares, debt, and multiple independently |
WallStSmart research model · Not financial advice · Past performance is not indicative of future results · Last researched: May 20, 2026.
CLBT price target FAQ
What is the CLBT price target for 2030?
WallStSmart's Cellebrite DI 2030 base case is $16.82 per share, with a bull case of $35.26 and bear case of $12.20. The NPV of the base case discounted to today at 11% WACC is $10.48.
How is the Cellebrite DI 2030 stock forecast calculated?
The CLBT 2030 projection multiplies projected revenue by a growth-adjusted P/S multiple to derive enterprise value, subtracts projected net debt to get equity value, then divides by diluted shares outstanding accounting for dilution from stock-based compensation and equity raises.
Why does the CLBT price target account for dilution?
Cellebrite DI is projected to grow diluted share count from 249M to 258M by 2030 (a 3% increase) through stock-based compensation and capital raises. Ignoring this would inflate the price target by approximately 3%.
What is the analyst consensus on CLBT stock?
5 analysts cover CLBT with an average 12-month price target of $21.75. The 2030 projection extends this framework with longer-horizon assumptions including dilution and time value of money.